Stocks Health care TBPH
NASDAQ · Health careTheravance Biopharma, Inc. (TBPH)
Theravance Biopharma, Inc. brought in $104.3M of revenue over the twelve months to June 30, 2026, up 35.1% from a year earlier. Net income was $53.8M, a net margin of 51.6%. Operating cash flow minus capital spending left $238.5M of free cash flow in fiscal 2025. At June 30, 2026 it held $219.8M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 11, 2026.
What Theravance Biopharma, Inc. does
Theravance Biopharma, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker TBPH.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $107.5M | $105.9M | $2.06 | $238.5M |
| 2024 | $64.4M | -$56.4M | -$1.15 | -$11.9M |
| 2023 | $57.4M | -$55.2M | -$1.00 | -$29.5M |
| 2022 | $51.3M | $872.1M | $11.85 | -$187.6M |
| 2021 | $55.3M | -$199.4M | -$2.87 | -$211.3M |
| 2020 | $71.9M | -$278M | -$4.46 | -$257M |
Latest SEC filings
What Theravance Biopharma, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 25, 2026Activist stake changed SCHEDULE 13D/A
- September 24, 2026Form S-8 POS filing S-8 POS
- September 24, 2026Form S-8 POS filing S-8 POS
- September 24, 2026Form S-8 POS filing S-8 POS
- September 24, 2026Form S-8 POS filing S-8 POS
- September 24, 2026Form S-8 POS filing S-8 POS
- September 24, 2026Form S-8 POS filing S-8 POS
- September 24, 2026Form S-8 POS filing S-8 POS
- September 24, 2026Form S-8 POS filing S-8 POS
- September 24, 2026Form S-8 POS filing S-8 POS
Questions about TBPH
What does Theravance Biopharma, Inc. do?
Theravance Biopharma, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker TBPH.
Is Theravance Biopharma, Inc. profitable?
Yes. Over the twelve months to June 30, 2026 it reported net income of $53.8M on revenue of $104.3M, a net margin of 51.6%.
How much revenue does Theravance Biopharma, Inc. make?
Over the twelve months to June 30, 2026 Theravance Biopharma, Inc. reported revenue of $104.3M. That is 35.1% more than a year earlier.
When did Theravance Biopharma, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 11, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the activist stake changed from September 25, 2026.
Similar companies
Follow TBPH
Get an email when Theravance Biopharma, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow TBPH: get an email when it filesWhere the numbers come from
Financial figures are the values Theravance Biopharma, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.